Bone and soft tissue sarcomas, tumors of the skinBone and soft tissue sarcomas, tumors of the skinСаркомы костей, мягких тканей и опухоли кожи2219-46142782-3687Publishing House ABV Press64510.17650/2219-4614-2024-16-1-25-33REVIEWSОБЗОРНЫЕ СТАТЬИComponents of the microenvironment of soft tissue sarcomas. Part IКомпоненты микроокружения сарком мягких тканей. Часть 1https://orcid.org/0000-0001-8077-2307LokhoninaA. V.ЛохонинаА. В.
Russian Federation

6 Miklukho-Maklaya St., Moscow 117198

4 Akademika Oparina St., Moscow 117997

 

117198 Москва, ул. Миклухо-Маклая, 6

117997 Москва, ул. Академика Опарина, 4

117198 Москва, ул. Миклухо-Маклая, 6

https://orcid.org/0000-0002-8226-0433JumaniyazovaE. D.ДжуманиязоваЭ. Д.
Russian Federation

6 Miklukho-Maklaya St., Moscow 117198

Энар Денисовна Джуманиязова

117198 Москва, ул. Миклухо-Маклая, 6

enar2017@yandex.ruhttps://orcid.org/0000-0002-1337-7160DzhalilovaD. Sh.ДжалиловаД. Ш.
Russian Federation

6 Miklukho-Maklaya St., Moscow 117198

117198 Москва, ул. Миклухо-Маклая, 6

117418 Москва, ул. Цюрупы, 3

https://orcid.org/0000-0002-6182-1799KosyrevaA. M.КосыреваА. М.
Russian Federation

6 Miklukho-Maklaya St., Moscow 117198

3 Tsyurupy St., Moscow 117418

117198 Москва, ул. Миклухо-Маклая, 6

117418 Москва, ул. Цюрупы, 3

https://orcid.org/0000-0002-3532-983XKazaryanG. G.КазарянГ. Г.
Russian Federation

6 Miklukho-Maklaya St., Moscow 117198

117198 Москва, ул. Миклухо-Маклая, 6

https://orcid.org/0000-0002-6498-5764FatkhudinovT. Kh.ФатхудиновТ. Х.
Russian Federation

6 Miklukho-Maklaya St., Moscow 117198

3 Tsyurupy St., Moscow 117418

117198 Москва, ул. Миклухо-Маклая, 6

117418 Москва, ул. Цюрупы, 3

Scientific Research Institute of Molecular and Cellular Medicine of the Peoples’ Friendship University of RussiaНаучно-исследовательский институт молекулярной и клеточной медицины ФГАОУ ВО «Российский университет дружбы народов»National Medical research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава РоссииMedical Institute of the Peoples’ Friendship University of RussiaМедицинский институт ФГАОУ ВО «Российский университет дружбы народов»Research Institute of Human Morphology of the B.V. Petrovsky Russian Scientific Center of SurgeryНаучно-исследовательский институт морфологии человека им. акад. А.П. Авцына ФГБНУ «Российский научный центр хирургии им. акад. Б.В. Петровского»0804202416125330804202408042024Copyright ©; 2024, Lokhonina A.V., Jumaniyazova E.D., Dzhalilova D.S., Kosyreva A.M., Kazaryan G.G., Fatkhudinov T.K.Copyright ©; 2024, Лохонина А.В., Джуманиязова Э.Д., Джалилова Д.Ш., Косырева А.М., Казарян Г.Г., Фатхудинов Т.Х.2024Lokhonina A.V., Jumaniyazova E.D., Dzhalilova D.S., Kosyreva A.M., Kazaryan G.G., Fatkhudinov T.K.Лохонина А.В., Джуманиязова Э.Д., Джалилова Д.Ш., Косырева А.М., Казарян Г.Г., Фатхудинов Т.Х.https://creativecommons.org/licenses/by/4.0https://sarbon.abvpress.ru/jour/article/view/645

Soft tissue sarcomas (STS) are a rare heterogeneous group of malignant neoplasms characterized by aggressive course and poor response to treatment. This determines the relevance of research aimed at studying the pathogenesis of STS. The tumor microenvironment consists of stromal, immune cells, blood, lymphatic vessels, and extracellular matrix. By now, it is known that STS is characterized by complex relationships between tumor cells and components of the microenvironment. Dynamic interactions between tumor cells and components of the microenvironment enhance adaptation to changing environmental conditions, which provides high aggressive potential of STS and resistance to antitumor therapy. Basic research aimed at investigating the role of microenvironmental components in STS carcinogenesis may serve as a key to the discovery of both new prognostic predictor biomarkers and targets for new antitumor drugs. This review article is devoted to the role and interaction of STS cells with components of the microenvironment.

Саркомы мягких тканей (СМТ) – редкая гетерогенная группа злокачественных новообразований, характеризующаяся агрессивным течением и плохим ответом на лечение. Это обусловливает актуальность исследований, направленных на изучение патогенеза данной патологии. Опухолевое микроокружение состоит из стромальных и иммунных клеток, кровеносных и лимфатических сосудов, а также внеклеточного матрикса. К настоящему времени известно, что для СМТ характерны сложные взаимоотношения между опухолевыми клетками и компонентами микроокружения. Динамические взаимодействия между ними усиливают адаптацию к меняющимся условиям окружающей среды, что обеспечивает высокий агрессивный потенциал СМТ и устойчивость к противоопухолевой терапии. Фундаментальные исследования, направленные на изучение роли компонентов микроокружения в канцерогенезе СМТ, могут послужить ключом к открытию как новых биомаркеров – предикторов прогноза, так и мишеней для противоопухолевых препаратов. Данная статья посвящена роли компонентов микроокружения СМТ в канцерогенезе и их взаимодействию с клетками этой опухоли.

soft tissue sarcomastumour microenvironmentimmune cellsmacrophageslymphocytesneoangiogenesisсаркомы мягких тканеймикроокружение опухолииммунные клеткимакрофагилимфоцитынеоангиогенезThe work was supported by the Russian Science Foundation (grant No. 23-65-00003).Работа выполнена при поддержке Российского научного фонда (грант № 23-65-00003).Blay J.Y. Evolution in soft tissue sarcoma. Future Oncol 2017;13(1s):1–2. DOI: 10.2217/fon-2016-0497Almas T., Khan M.K., Murad M.F. et al. Clinical and pathological characteristics of soft tissue sarcomas: a retrospective study from a developing country. Cureus 2020;12(8):e9913. DOI: 10.7759/cureus.9913Ramu E.M., Houdek M.T., Isaac C.E. et al. Management of soft-tissue sarcomas; treatment strategies, staging, and outcomes. SICOT J 2017;3:20. DOI: 10.1051/sicotj/2017010Gerrand C.H., Bell R.S., Wunder J.S. et al. The influence of anatomic location on outcome in patients with soft tissue sarcoma of the extremity. Cancer 2003;97(2):485–92. DOI: 10.1002/cncr.11076Chintamani. Soft tissue sarcomas-the pitfalls in diagnosis and management. Indian J Surg Oncol 2011;2(4):261–4. DOI: 10.1007/s13193-012-0141-7Hatina J., Kripnerova M., Houfkova K. et al. Sarcoma stem cell heterogeneity. Adv Exp Med Biol 2019;1123:95–118. DOI: 10.1007/978-3-030-11096-3_7Zeng D., Li M., Zhou R., Zhang J. et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol Res 2019;7(5):737–50. DOI: 10.1158/2326-6066.CIR-18-0436Deng J., Zeng W., Kong W. et al. The study of sarcoma microenvironment heterogeneity associated with prognosis based on an immunogenomic landscape analysis. Front Bioeng Biotechnol 2020;8:1003. DOI: 10.3389/fbioe.2020.01003Wang Q., Shao X., Zhang Y. et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med 2023;12(10):11149–65. DOI: 10.1002/cam4.5698Tessaro F.H., Ko E.Y., De Simone M. et al. Single-cell RNA-seq of a soft-tissue sarcoma model reveals the critical role of tumorexpressed MIF in shaping macrophage heterogeneity. Cell Rep 2022;39(12):110977. DOI: 10.1016/j.celrep.2022.110977Petitprez F., de Reyniès A., Keung E.Z. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 2020;577(7791):556–60. DOI: 10.1038/s41586-019-1906-8Stahl D., Gentles A.J., Thiele R. et al. Prognostic profiling of the immune cell microenvironment in Ewing’s Sarcoma Family of Tumors. Oncoimmunology 2019;8(12):e1674113. DOI: 10.1080/2162402X.2019.1674113Hu C., Chen B., Huang Z. et al. Comprehensive profiling of immunerelated genes in soft tissue sarcoma patients. J Translat Med 2020;18:1–18. DOI: 10.1186/s12967-020-02512-8Gu H.Y., Lin L.L., Zhang C. et al. The potential of five immune-related prognostic genes to predict survival and response to immune checkpoint inhibitors for soft tissue sarcomas based on multi-omic study. Front Oncol 2020;10:1317. DOI: 10.3389/fonc.2020.01317Tsagozis P., Augsten M., Zhang Y. et al. An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma. Cancer Immunol Immunother 2019;68(6):927–36. DOI: 10.1007/s00262-019-02322-yDufresne A., Lesluyes T., Ménétrier-Caux C. et al. Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma. Oncoimmunology 2020;9(1):1792036. DOI: 10.1080/2162402X.2020.1792036Zhu N., Hou J. Assessing immune infiltration and the tumor microenvironment for the diagnosis and prognosis of sarcoma. Cancer Cell Int 2020;20(1):1–11. DOI: 10.1186/s12935-020-01672-3Zhou J., Tang Z., Gao S. et al. Tumor-associated macrophages: recent insights and therapies. Front Oncol 2020;10:188. DOI: 10.3389/fonc.2020.00188Mantovani A., Marchesi F., Malesci A. et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017;14(7):399–416. DOI: 10.1038/nrclinonc.2016.217Najafi M., Hashemi Goradel N., Farhood B. et al. Macrophage polarity in cancer: a review. J Cell Biochem 2019;120(3):2756–65. DOI: 10.1002/jcb.27646Nyström H., Jönsson M., Nilbert M. et al. Immune-cell infiltration in high-grade soft tissue sarcomas; prognostic implications of tumorassociated macrophages and B-cells. Acta Oncol 2023;62(1):33–9. DOI: 10.1080/0284186X.2023.2172688Seong G., D’Angelo S.P. New therapeutics for soft tissue sarcomas: overview of current immunotherapy and future directions of soft tissue sarcomas. Front Oncol 2023;13:1150765. DOI: 10.3389/fonc.2023.1150765Cheng S., Li Z., Gao R., Xing B. et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 2021;184(3):792–809. DOI: 10.1016/j.cell.2021.01.010El-Kenawi A., Dominguez-Viqueira W., Liu M. et al. Macrophagederived cholesterol contributes to therapeutic resistance in prostate cancer. Cancer Res 2021;81(21):5477–90. DOI: 10.1158/0008-5472.CAN-20-4028Cassetta L., Pollard J.W. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov 2018;17(12):887–904. DOI: 10.1038/nrd.2018.169Fujiwara T., Yakoub M.A., Chandler A. et al. CSF1/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment. Mol Cancer Ther 2021;20(8):1388–99. DOI: 10.1158/1535-7163.MCT-20-0591Lee C.H., Espinosa I., Vrijaldenhoven S. et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res 2008;14(5):1423–30. DOI: 10.1158/1078-0432.CCR-07-1712Nabeshima A., Matsumoto Y., Fukushi J. et al.Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/ Akt pathways. B J Cancer 2015;112(3):547–55. DOI: 10.1038/bjc.2014.637Oike N., Kawashima H., Ogose A. et al. Prognostic impact of the tumor immune microenvironment in synovial sarcoma. Cancer Sci 2018;109(10):3043–54. DOI: 10.1111/cas.13769Kather J.N., Hörner C., Weis C.A. et al. CD163+ immune cell infiltrates and presence of CD54+ microvessels are prognostic markers for patients with embryonal rhabdomyosarcoma. Sci Rep 2019;9(1):9211. DOI: 10.1038/s41598-019-45551-yMinopoli M., Sarno S., Cannella L. et al. Crosstalk between macrophages and myxoid liposarcoma cells increases spreading and invasiveness of tumor cells. Cancers 2021;13(13):3298. DOI: 10.3390/cancers13133298Qayoom H., Sofi S., Mir M.A. Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis. Immunol Res 2023;71(4):588–99. DOI: 10.1007/s12026-023-09376-2Badalamenti G., Fanale D., Incorvaia L. et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? Cell Immunol 2019;343:103753. DOI: 10.1016/j.cellimm.2018.01.013Smolle M.A., Herbsthofer L., Granegger B. et al. T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: A clinicopathological study. Br J Cancer 2021;25(5):717–24. DOI: 10.1038/s41416-021-01456-0Hemminger J.A., Iwenofu O.H. NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms. Mod Pathol 2013;26(9):1204–10. DOI: 10.1038/modpathol.2013.65Sorbye S.W., Kilvaer T., Valkov A. et al. Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One 2011;6(1):e14611. DOI: 10.1371/journal.pone.0014611Pollack S.M., He Q., Yearley J.H. et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed deathligand 1 expression in patients with soft tissue sarcomas. Cancer 2017;123(17):3291–304. DOI: 10.1002/cncr.30726Nakajima K., Raz A. T-cell infiltration profile in musculoskeletal tumors. J Orthop Res 2021;39(3):536–42. DOI: 10.1002/jor.24890Fujii H., Arakawa A., Utsumi D. et al. CD8+ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma. Int Journal Cancer 2014;134(10):2393–402. DOI: 10.1002/ijc.28581Van Erp A.E., Versleijen-Jonkers Y.M., Hillebrandt-Roeffen M.H. et al. Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. Oncotarget 2017;8(41):71371. DOI: 10.18632/oncotarget.19071Nowicki T.S., Akiyama R., Huang R.R. et al. Infiltration of CD8 T cells and expression of PD-1 and PD-L1 in synovial sarcoma. Cancer Immunol Res 2017;5(2):118–26. DOI: 10.1158/2326-6066.CIR-16-0148Liu Y., Cao X. Immunosuppressive cells in tumor immune escape and metastasis. J Mol Med 2016;94(5):509–22. DOI: 10.1007/s00109-015-1376-xD’Angelo S.P., Shoushtari A.N., Agaram N.P. et al. Prevalence of tumorinfiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Human Pathol 2015;46(3):357–65. DOI: 10.1016/j.humpath.2014.11.001Li L.J., Shi Y.C., Luo M.X. et al. Effects of moxibustion on Treg cells in sarcoma microenvironment. Journal of Integrative Medicine 2021;19(3):251–7. DOI: 10.1016/j.joim.2021.02.001Que Y., Xiao W., Guan Y.X. et al. PD-L1 expression is associated with FOXP3+ regulatory T-cell infiltration of soft tissue sarcoma and poor patient prognosis. J Cancer 2017;8(11):2018. DOI: 10.7150/jca.18683Keung E.Z., Burgess M., Salazar R. et al. Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab. Clin Cancer Res 2020;26(6):1258–66. DOI: 10.1158/1078-0432.CCR-19-1824Judge S.J., Darrow M.A., Thorpe S.W. et al. Analysis of tumorinfiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas. J Immunother Cancer 2020;8(2):e001355. DOI: 10.1136/jitc-2020-001355Sharonov G.V., Serebrovskaya E.O., Yuzhakova D.V. et al. B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nature Rev Immunol 2020;20(5):294–307. DOI: 10.1038/s41577-019-0257-xPremkumar K., Shankar B.S. TGF-βR inhibitor SB431542 restores immune suppression induced by regulatory B–T cell axis and decreases tumour burden in murine fibrosarcoma. Cancer Immunol Immunother 2021;70(1):153–68. DOI: 10.1007/s00262-020-02666-wTseng W.W., Malu S., Zhang M. et al. Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. Sarcoma 2015;2015:547460. DOI: 10.1155/2015/547460Sorbye S.W., Kilvaer T.K., Valkov A. et al. Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas. BMC Clin Pathol 2012;12(1):1–11. DOI: 10.1371/journal.pone.0014611Sorbye S.W., Kilvaer T.K., Valkov A. et al. Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clin Pathol 2012;12(1):1–10. DOI: 10.1186/1472-6890-12-5Lazar A.J., McLellan M.D., Bailey M.H. et al. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 2017;171(4):950–65. DOI: 10.1016/j.cell.2017.10.014Sousa L.M., Almeida J.S., Fortes-Andrade T. et al. Tumor and peripheral immune status in soft tissue sarcoma: implications for immunotherapy. Cancers 2021;13(15):3885. DOI: 10.3390/cancers13153885Ponzetta A., Carriero R., Carnevale S. et al. Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human tumors. Cell 2019;178(2):346–60. DOI: 10.1016/j.cell.2019.05.047Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer 2016;16(9):582–98. DOI: 10.1038/nrc.2016.73Joshi R.S., Kanugula S.S., Sudhir S. et al. The role of cancer-associated fibroblasts in tumor progression. Cancers 2021;13(6):1399. DOI: 10.3390/cancers13061399LeBleu V.S., Kalluri R. A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis Model Mech 2018;11(4):dmm029447. DOI: 10.1242/dmm.029447Erdogan B., Webb D.J. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans 2017;45(1):229–36. DOI: 10.1042/BST20160387Kudo A., Yoshimoto S., Yoshida H. et al. Biological features of canine cancer-associated fibroblasts and their influence on cancer cell invasion. J Vet Med Sci 2022;84(6):784–91. DOI: 10.1292/jvms.22-0041Feng C., Kou L., Yin P. et al. Excessive activation of IL­33/ST2 in cancer­associated fibroblasts promotes invasion and metastasis in ovarian cancer. Oncol Lett 2022;23(5):1–12. DOI: 10.3892/ol.2022.13278Komohara Y., Takeya M. CAFs and TAMs: maestros of the tumour microenvironment. J Pathol 2017;241(3):313–5. DOI: 10.1002/path.4824Harati K., Daigeler A., Hirsch T. et al. Tumor-associated fibroblasts promote the proliferation and decrease the doxorubicin sensitivity of liposarcoma cells. Int J Mol Med 2016;37(6):1535–41. DOI: 10.3892/ijmm.2016.2556Wright K., Ly T., Kriet M. et al. Cancer-associated fibroblasts: master tumor microenvironment modifiers. Cancers 2023;1(6):1899. DOI: 10.3390/cancers15061899Huang H., Wang Z., Zhang Y. et al Mesothelial cell-derived antigenpresenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell 2022;40(6):656–73. DOI: 10.1016/j.ccell.2022.04.011Mao X., Xu J., Wang W., Liang C. et al. Crosstalk between cancerassociated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer 2021;20(1):1–30. DOI: 10.1186/s12943-021-01428-1Manzur M., Hamzah J., Ganss R. Modulation of the “blood-tumor” barrier improves immunotherapy. Cell Cycle 2008;7(16):2452–5. DOI: 10.4161/cc.7.16.6451Lee C.T., Mace T., Repasky E.A. Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer? Int J Hyperthermia 2010;26(3):232–46. DOI: 10.3109/02656731003601745Nordsmark M., Alsner J., Keller J. et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001;84(8):1070–5. DOI: 10.1054/bjoc.2001.1728Pouysségur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441(7092): 437–43. DOI: 10.1038/nature04871Aggerholm-Pedersen N., Sørensen B.S., Overgaard J. et al. A prognostic profile of hypoxia-induced genes for localised high-grade soft tissue sarcoma. Br J Cancer 2016;115(9):1096–104. DOI: 10.1038/bjc.2016.310Nyström H., Jönsson M., Werner-Hartman L. et al. Hypoxia-inducible factor 1α predicts recurrence in high-grade soft tissue sarcoma of extremities and trunk wall. J Clin Pathol 2017;70(10):879–85. DOI: 10.1136/jclinpath-2016-204149Pakos E.E., Goussia A.C., Tsekeris P.G. et al. Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res 2005;25(5):3591–6.Yudoh K., Kanamori M., Ohmori K. et al. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 2001;84(12):1610–5. DOI: 10.1054/bjoc.2001.1837Hayes A.J., Mostyn-Jones A., Koban M.U. et al. Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg 2004;91(2):242–7. DOI: 10.1002/bjs.4398Tomlinson J., Barsky S.H., Nelson S. et al. Different patterns of angiogenesis in sarcomas and carcinomas. Clin Cancer Res 1999;5(11):3516–22.Tammela T., Zarkada G., Wallgard E. et al. VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008;454(7204):656–60. DOI: 10.1038/nature07083Yoon S.S., Segal N.H., Park P.J. et al. Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Res 2006;135(2):282–90. DOI: 10.1016/j.jss.2006.01.023Kilvaer T.K., Valkov A., Sorbye S.W. Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients. J Transl Med 2011;9:104. DOI: 10.1186/1479-5876-9-104Rocchi L., Caraffi S., Perris R. et al. The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets. Biosci Rep 2014;34(6):e00147. DOI: 10.1042/BSR20140075